These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21353324)

  • 41. HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review.
    Thibault C; Khodari W; Lequoy M; Gligorov J; Belkacémi Y
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):123-33. PubMed ID: 23566949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
    Forest F; Yvorel V; Karpathiou G; Stachowicz ML; Vergnon JM; Fournel P; Tiffet O; Trombert B; Péoc'h M
    Hum Pathol; 2016 Mar; 49():99-106. PubMed ID: 26826416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
    Li BT; Lee A; O'Toole S; Cooper W; Yu B; Chaft JE; Arcila ME; Kris MG; Pavlakis N
    Lung Cancer; 2015 Dec; 90(3):617-9. PubMed ID: 26559459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer.
    Bu S; Wang R; Pan Y; Yu S; Shen X; Li Y; Sun Y; Chen H
    Ann Surg Oncol; 2017 Jan; 24(1):291-297. PubMed ID: 27008586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
    Offin M; Feldman D; Ni A; Myers ML; Lai WV; Pentsova E; Boire A; Daras M; Jordan EJ; Solit DB; Arcila ME; Jones DR; Isbell JM; Beal K; Young RJ; Rudin CM; Riely GJ; Drilon A; Tabar V; DeAngelis LM; Yu HA; Kris MG; Li BT
    Cancer; 2019 Dec; 125(24):4380-4387. PubMed ID: 31469421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
    Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
    J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice.
    Burandt E; Schreiber M; Stein A; Minner S; Clauditz TS; Bokemeyer C; Jänicke F; Fisch M; Izbicki JR; Knecht R; Sauter G; Stahl PR
    Genes Chromosomes Cancer; 2014 Mar; 53(3):228-39. PubMed ID: 24311521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
    Lai WV; Lebas L; Barnes TA; Milia J; Ni A; Gautschi O; Peters S; Ferrara R; Plodkowski AJ; Kavanagh J; Sabari JK; Clarke SJ; Pavlakis N; Drilon A; Rudin CM; Arcila ME; Leighl NB; Shepherd FA; Kris MG; Mazières J; Li BT
    Eur J Cancer; 2019 Mar; 109():28-35. PubMed ID: 30685684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
    Pillai RN; Behera M; Berry LD; Rossi MR; Kris MG; Johnson BE; Bunn PA; Ramalingam SS; Khuri FR
    Cancer; 2017 Nov; 123(21):4099-4105. PubMed ID: 28743157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.
    Buttitta F; Barassi F; Fresu G; Felicioni L; Chella A; Paolizzi D; Lattanzio G; Salvatore S; Camplese PP; Rosini S; Iarussi T; Mucilli F; Sacco R; Mezzetti A; Marchetti A
    Int J Cancer; 2006 Dec; 119(11):2586-91. PubMed ID: 16988931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of Recurrent Activating
    Lorch G; Sivaprakasam K; Zismann V; Perdigones N; Contente-Cuomo T; Nazareno A; Facista S; Wong S; Drenner K; Liang WS; Amann JM; Sinicropi-Yao SL; Koenig MJ; La Perle K; Whitsett TG; Murtaza M; Trent JM; Carbone DP; Hendricks WPD
    Clin Cancer Res; 2019 Oct; 25(19):5866-5877. PubMed ID: 31431454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
    Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ
    Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer.
    Vallböhmer D; Brabender J; Yang DY; Danenberg K; Schneider PM; Metzger R; Holscher AH; Danenberg PV
    Clin Lung Cancer; 2006 Mar; 7(5):332-7. PubMed ID: 16640805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
    Falchook GS; Janku F; Tsao AS; Bastida CC; Stewart DJ; Kurzrock R
    J Thorac Oncol; 2013 Feb; 8(2):e19-20. PubMed ID: 23328556
    [No Abstract]   [Full Text] [Related]  

  • 55. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
    Pahuja KB; Nguyen TT; Jaiswal BS; Prabhash K; Thaker TM; Senger K; Chaudhuri S; Kljavin NM; Antony A; Phalke S; Kumar P; Mravic M; Stawiski EW; Vargas D; Durinck S; Gupta R; Khanna-Gupta A; Trabucco SE; Sokol ES; Hartmaier RJ; Singh A; Chougule A; Trivedi V; Dutt A; Patil V; Joshi A; Noronha V; Ziai J; Banavali SD; Ramprasad V; DeGrado WF; Bueno R; Jura N; Seshagiri S
    Cancer Cell; 2018 Nov; 34(5):792-806.e5. PubMed ID: 30449325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HER2 mutations in Chinese patients with non-small cell lung cancer.
    Song Z; Yu X; Shi Z; Zhao J; Zhang Y
    Oncotarget; 2016 Nov; 7(47):78152-78158. PubMed ID: 27825109
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
    Fan Y; Qiu J; Yu R; Cao R; Chen X; Ou Q; Wu X; Shao YW; Nagasaka M; Zhang J; Ou SI
    Mol Oncol; 2020 Aug; 14(8):1731-1739. PubMed ID: 32478891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LKB1 gene mutations in Japanese lung cancer patients.
    Onozato R; Kosaka T; Achiwa H; Kuwano H; Takahashi T; Yatabe Y; Mitsudomi T
    Cancer Sci; 2007 Nov; 98(11):1747-51. PubMed ID: 17711506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.
    Kumagai T; Tomita Y; Nakatsuka SI; Kimura M; Kunimasa K; Inoue T; Tamiya M; Nishino K; Susaki Y; Kusu T; Tokunaga T; Okami J; Higashiyama M; Imamura F
    Thorac Cancer; 2018 Apr; 9(4):466-471. PubMed ID: 29473311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.
    Wen W; Chen WS; Xiao N; Bender R; Ghazalpour A; Tan Z; Swensen J; Millis SZ; Basu G; Gatalica Z; Press MF
    J Mol Diagn; 2015 Sep; 17(5):487-95. PubMed ID: 26320869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.